Insitro has raised a total of $643 million across multiple funding rounds, with its largest being a $400 million Series C round in March 2021. The South San Francisco-based company is transforming drug discovery and development using a machine learning-driven platform that integrates in vitro cellular data with clinical datasets. Insitro's technology accelerates therapeutic programs in areas such as metabolism, oncology, and neuroscience, helping biopharma companies reduce the time and cost associated with traditional drug development.
Keep reading to explore Insitro's funding journey, key investors, and what's next for this biotech innovator.
What Is Insitro and What Does It Do?
Founded in 2018 by Daphne Koller, Insitro is headquartered in South San Francisco, California. The company leverages machine learning and high-throughput biology to revolutionise drug discovery, combining experimental and clinical data to accelerate development timelines. Insitro's platform supports therapeutic programs across metabolism, oncology, and neuroscience, enabling data-driven decisions for more effective treatments.
With a team of 251–500 employees, Insitro is advancing AI-powered biology to improve drug discovery efficiency, reduce costs, and uncover new therapeutic opportunities in the biotech sector.
How Much Funding Has Insitro Raised?
- Series A
- Amount Raised: $100M
- Date: May 2018
- Motivation: To establish the foundational technology and initial team for Insitro's machine learning-driven drug discovery platform.
- Series B
- Amount Raised: $143M
- Date: May 2020
- Lead Investors: Andreessen Horowitz
- Motivation: To expand capabilities in high-throughput biology and machine learning integration.
- Series C
- Amount Raised: $400M
- Date: March 2021
- Lead Investors: CPP Investments
- Motivation: To further expand platform capabilities, pipeline, and access, enabling datasets, technologies, and potential in-licensed assets.
Total Funding Raised: $643M
Current Valuation: Not publicly disclosed
Latest Funding Date: March 1, 2021
Key Investors
- CPP Investments
- Details: Professional investment management organisation managing Canada Pension Plan funds, focusing on sustainable long-term returns.
- Investment Focus Areas: Healthcare, technology, infrastructure
- Notable Investments: Enbridge, Alibaba, Glencore
- Andreessen Horowitz
- Details: Private venture capital firm investing in technology companies across stages, with a strong track record in biotech and tech startups.
- Investment Focus Areas: Technology, healthcare, fintech
- Notable Investments: Facebook, Airbnb, Slack
- BlackRock
- Details: Global investment management corporation managing assets across multiple sectors.
- Investment Focus Areas: Technology, healthcare, financial services
- Notable Investments: Apple, Microsoft, Alphabet
- ARCH Venture Partners
- Details: VC firm focusing on early-stage technology and biotech companies with groundbreaking potential.
- Investment Focus Areas: Biotechnology, life sciences, technology
- Notable Investments: Illumina, Alnylam Pharmaceuticals, Juno Therapeutics
- GV (formerly Google Ventures)
- Details: Venture capital arm of Alphabet Inc., investing in technology and life sciences.
- Investment Focus Areas: Technology, life sciences, healthcare
- Notable Investments: Uber, Nest, Slack
Where Is Insitro's Headquarters?
Insitro is headquartered in South San Francisco, California, a hub for biotechnology innovation. Its location enables collaboration with leading research institutions, biopharma companies, and access to top talent in machine learning and drug discovery.
What's Next for Insitro?
Insitro is poised for continued growth through its machine learning-driven platform, strategic collaborations, and expansion of therapeutic pipelines. The Series C funding of $400 million supports platform enhancement and partnerships with companies like Gilead and Bristol Myers Squibb, targeting conditions such as NASH and ALS.
Future fundraising opportunities are promising, bolstered by long-term investors like CPP Investments and new backers, including Temasek and SoftBank. Challenges include integrating AI into drug discovery and managing complex collaborations, but Insitro's data-driven approach positions it as a leader in biotech innovation.
Get Investor & Funding Insights with TexAu
TexAu provides detailed fundraising information on companies like Insitro. Track investors, monitor funding rounds, and gather actionable insights to strengthen your sales and business strategy.
Sign Up for Free on TexAu and turn data into smarter, faster business decisions.
